Evidence map›Paper›PMID 35735593›Full record

ReviewBiomimetics (Basel, Switzerland)2022

Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.

Md Mohosin Rana, Marites P Melancon

Open access · goldAbstract readReview
In one paragraph

Review in Biomimetics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Md Mohosin RanaBiomedical Engineering Graduate Program, Schulich School of Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0003-3299-6538
Marites P MelanconDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-7447-0705
The University of Texas MD Anderson Cancer Center · USUniversity of Calgary · CA

Funding

Nanoparticle- Infused Radiopaque Absorbable Medical DeviceR01HL141831 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2018 to 2022
$1.9M
Biodegradable Radiopaque Polymeric Scaffolds Loaded with Mesenchymal Stem Cells for Image-Guided Arteriovenous Fistula Maturation and Long-Term PatencyR01HL159960 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2022 to 2025
$1.6M
National Heart Lung and Blood Institute 1R01HL159960-01A1National Heart Lung and Blood Institute 5R01HL141831-03NHLBI NIH HHS R01 HL141831NHLBI NIH HHS R01 HL159960
6 · The paper itself

Abstract

Minimally invasive endovascular embolization is a widely used clinical technique used for the occlusion of blood vessels to treat various diseases. Different occlusive agents ranging from gelatin foam to synthetic polymers such as poly(vinyl alcohol) (PVA) have been commercially used for embolization. However, these agents have some drawbacks, such as undesired toxicity and unintended and uncontrolled occlusion. To overcome these issues, several polymer-based embolic systems are under investigation including biocompatible and biodegradable microspheres, gelling liquid embolic with controlled occlusive features, and trackable microspheres with enhanced safety profiles. This review aims to summarize recent advances in current and emerging polymeric materials as embolization agents with varying material architectures. Furthermore, this review also explores the potential of combining injectable embolic agents and cell therapy to achieve more effective embolization with the promise of outstanding results in treating various devastating diseases. Finally, limitations and challenges in developing next-generation multifunctional embolic agents are discussed to promote advancement in this emerging field.

Indexed as

arteriovenous malformationsembolic agentsembolizationhepatocellular carcinomapolymersuterine fibroids

Identifiers

PMID35735593
PMCPMC9221114
OpenAlexW4282021210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.